Detail akcie Femasys Rg online

Business Summary: Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Femasys Inc revenues increased 41% to $1.5M. Net loss increased 7% to $14.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Basic Earnings per Share excluding Extraordinary Items increased from -$0.62 to -$0.50.